inne

inne, a biotech startup headquartered in Germany, is revolutionizing women's health with its innovative approach to tracking fertility. Founded in 2016, inne leverages biochemistry to offer a convenient at-home saliva test that measures daily progesterone levels, predicting and confirming ovulation with precision.

Their unique product, the inne minilab, integrates with a user-friendly app to provide insights into hormone levels and fertility cycles. This empowers women to make informed decisions about their reproductive health. The company's mission resonates with the growing demand for personalized health solutions, making them a promising player in the Biotechnology and Health and Wellness industries.

inne secured a $10.00M Series A investment on May 1, 2022, supported by notable investors such as Borski Fund, DSM Venturing, Calm/Storm, and industry pioneers Rolf Schrömgens and Taavet Hinrikus. The startup's commitment to pushing the boundaries of science and technology positions it as a compelling investment opportunity in the health tech sector.